High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: diagnostic value, relation to serum neuron specific enolase, and staging.
Aged; Bronchoalveolar Lavage Fluid/chemistry; Carcinoma, Non-Small-Cell Lung/blood/chemistry/diagnosis; Carcinoma, Small Cell/blood/chemistry/diagnosis; Female; Humans; Lung Diseases, Obstructive/diagnosis/pathology; Lung Neoplasms/blood/chemistry/diagnosis; Male; Middle Aged; Neoplasm Staging; Phosphopyruvate Hydratase/analysis/blood; Predictive Value of Tests; Sensitivity and Specificity; Smoking
Abstract :
[en] BACKGROUND: High levels of neuron specific enolase (NSE) have recently been described in the bronchoalveolar lavage (BAL) fluid of patients with lung carcinoma. Although its value in serum has been extensively studied, its diagnostic value in BAL fluid in terms of sensitivity, specificity, and predictive value have not been evaluated. In addition, its value in staging and relation to serum NSE are yet unknown. METHODS: NSE levels were determined on the same day in the BAL fluid and the sera of two groups of patients: those with newly diagnosed lung carcinoma and those with smoking related chronic obstructive pulmonary disease (COPD). Clinical TNM staging was also performed. Levels of NSE in BAL fluid were expressed as nanograms per 100 international units of lactate dehydrogenase. BAL fluid NSE levels of the two groups were compared with staging and serum NSE. RESULTS: A highly significant difference exists in BAL NSE in the two groups. For diagnostic purposes, the simultaneous measurements of serum NSE increases its sensitivity, but specificity remains unchanged. No correlation exists between BAL NSE and serum NSE, tumor size, nodal status, or the presence of metastases. BAL NSE is a better predictor of malignancy than serum NSE. CONCLUSION: BAL fluid measurements of NSE may have diagnostic value, specially if it is simultaneously measured in the serum. However, our study does not show any value for this technique in staging of lung carcinoma. Also it has no correlation with serum NSE. Studies will have to be performed to determine if BAL NSE can predict chemotherapeutic sensitivity.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Dowlati, A
Bury, Thierry ; Université de Liège - ULiège > Département des sciences de la motricité > Physiologie humaine et physiologie de l'effort physique
CORHAY, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie
High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: diagnostic value, relation to serum neuron specific enolase, and staging.
Prados MC, Alvarez-Sala R, Blasco R, Chivato T, Garcia Satue JL, Garcia Rio FJ, et al. The clinical value of neuron-specific enolase as a tumor marker in bronchoalveolar lavage. Cancer 1994;74:1552-5.
Rennard SI, Ghafouri MO, Thompson AB, Linder J, Vaughan W, Jones K, et al. Fractional processing of sequential bronchoalveolar lavage to separate bronchial and alveolar samples. Am Rev Respir Dis 1990;141:208-17.
Klech H, Hutter C. Clinical guidelines and indications for bronchoalveolar lavage (BAL): report of the European Society of Pneumology Task Group on BAL. Eur Respir J 1990;3:937-74.
American Joint Committee on Cancer. Lung. In: Beahrs OH, Henson DE, Hutter RVP, editors. Manual for the staging of cancer. 4th ed. Philadelphia: JB Lippincott, 1992:115-22.
Stahel RA, Ginsberg R, Havermann K. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989;5:119.
Tapia FJ, Polak JM, Barbosa AJA, Bloom SR, Marangos PJ, Dermody C, et al. Neurone specific enolase is produced by neuroendocrine tumors. Lancet 1981;i:808-11.
Carney DN, Marangos PJ, Ihde DC, Bunn PA, Cohen MH, Minna JD, et al. Serum neuron specific enolase: a marker for disease extent and response to therapy of small cell lung cancer. Lancet 1982;1:583-5.
Bergh J, Esscher T, Steinholtz L, Nilsson K, Pahlman S. Immunocytochemical demonstration of neuron specific enolase (NSE) in human lung cancers. Am J Clin Pathol 1985;84:1-7.
Dhillon AP, Rode J, Dhillon DP, Moss E, Thompson RJ, Spiro SG, et al. Neural markers in carcinoma of the lung. Br J Cancer 1985;51,645-52.
Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM. Neuroendocrine differentiation and clinical behavior in non-small cell lung tumors. Br J Cancer 1991;64:333-8.
Fujta K, Haimoto H, Imaizumi M, Abe T, Kato K. Evaluation of gammaenolase as a tumor marker for lung cancer. Cancer 1987;60:362-9.
Jarvisalo J, Hakama M, Knekt P, Sterman UH, Leino A, Teppo L, et al. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. Cancer 1993;71:1982-8.
Bergman B, Brizicka FT, Engstrom CP, Larsson S. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. Eur J Cancer 1993;29A:198-202.
De Diego A, Compte L, Sanchis J, Enguidanos MJ, Marco V. Usefulness of carcinoembryonic antigen determination in bronchoalveolar lavage fluid. Chest 1991;100:1060-3.
Scagliotti GV, Piani M, Gatti E, Gozzelino F, Albera C, Pozzi E. Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer. Eur Respir J 1989;2:746-50.
Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R, et al. Serum neuron-specific enolase is a useful tumour marker for small cell lung cancer. Cancer 1990;65:1386-90.
Johnson DH, Marangos PJ, Forbes JT, Hainsworth JD, Van Welch R, Hande KR, et al. Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. Cancer Res 1984;44:5409-14.
Cooper EH, Splinter TAW, Brown DA, Muers MF, Peake MD, Pearson SL. Evaluation of radioimmunoassay for neuron-specific enolase in small cell lung cancer. Br J Cancer 1985;52:333-8.
Quoix E, Charloux A, Popin E, Pauli G. Inability to predict disease extent in small cell lung cancer based on initial levels of serum neuron-specific enolase. Eur J Cancer 1993;16:2248-50.
Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non small cell lung cancer. J Clin Oncol 1989;7:1398-406.
Skov BG, Sorenson JB, Hirsch FR, Larsson LI, Hansen HH. Prognostic impact of histologic demonstration of chromogramn A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 1991;2:355-60.
Van Zandwijk N, Jassem E, Bonfrer JM, Mooi WJ, Van Tinteren H. Serum neuron specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol 1992;19(Suppl 2):37-43.